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Abstract  Bovine  viral  diarrhea  virus  (BVDV)  is  an  important  cause  of  economic  losses  world-
wide. E2  is  an  immunodominant  protein  and  a  promising  candidate  to  develop  subunit  vaccines.
To improve  its  immunogenicity,  a  truncated  E2  (tE2)  was  fused  to  a  single  chain  antibody  named
APCH, which  targets  to  antigen-presenting  cells.  APCH-tE2  and  tE2  proteins  were  expressed  in
the baculovirus  system  and  their  immunogenicity  was  ﬁrstly  compared  in  guinea  pigs.  APCH-tE2
vaccine was  the  best  one  to  evoke  a  humoral  response,  and  for  this  reason,  it  was  selected  for
a cattle  vaccination  experiment.  All  the  bovines  immunized  with  1.5  g  of  APCH-tE2  developed
high levels  of  neutralizing  antibodies  against  BVDV  up  to  a  year  post-immunization,  demon-
strating its  signiﬁcant  potential  as  a  subunit  vaccine.  This  novel  vaccine  is  undergoing  scale-up
and was  transferred  to  the  private  sector.  Nowadays,  it  is  being  evaluated  for  registration  as
the ﬁrst  Argentinean  subunit  vaccine  for  cattle.
© 2014  Asociación  Argentina  de  Microbiología.  Published  by  Elsevier  España,  S.L.U.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE Desarrollo  de  una  vacuna  de  subunidad  BVDV  mejorada  basada  en  la  glucoproteína  E2
Glucoproteína  E2;
Anticuerpo  de  cadena
fusionada  a  un  anticuerpo  de  cadena  simple  que  se  dirige  a  células  presentadoras
de  antígeno
diarrea  viral  bovina  (BVDV)  es  causante  de  importantes  pérdidas
l.  La  proteína  E2  es  la  inmunodominante  del  virus  y  es  la  candi-simple;
Vacuna  a  subunidad;
Baculovirus;
Resumen  El  virus  de  la  
económicas  a  nivel  mundia
data para  desarrollar  vacunas  de  subunidad.  Para  mejorar  su  inmunogenicidad,  una  versión
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Virus  de  la  diarrea
viral  bovina
truncada  de  la  E2  (tE2)  se  fusionó  a  un  anticuerpo  de  cadena  simple  (APCH),  que  se  dirige  a  las
células presentadoras  de  antígeno.  Se  expresaron  las  proteínas  APCH-tE2  y  tE2  en  el  sistema  de
baculovirus  y  su  inmunogenicidad  fue  evaluada  y  comparada  en  cobayos;  la  proteína  APCH-tE2
fue la  que  indujo  la  mejor  respuesta  humoral.  Por  dicha  razón  se  la  evaluó  en  bovinos  utilizando
1,5 g  de  antígeno.  Los  animales  presentaron  altos  títulos  de  anticuerpos  neutralizantes  contra
BVDV hasta  un  an˜o  posinmunización.  Esta  nueva  vacuna  está  en  proceso  de  escalado  y  se  trans-
ﬁrió al  sector  privado.  Actualmente  se  está  evaluando  para  su  registro  como  la  primera  vacuna
argentina  de  subunidad  para  bovinos.
© 2014  Asociación  Argentina  de  Microbiología.  Publicado  por  Elsevier  España,
S.L.U. Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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BBovine  viral  diarrhea  virus  (BVDV)  is  a  common  bovine
pathogen  that  belongs  to  the  family  Flaviviridae, Pestivirus
genus.  Several  clinical  conditions,  ranging  from  subclinical
to  severe  disease,  have  been  associated  with  this  agent.
Infections  with  BVDV  are  endemic  in  cattle  populations
worldwide  and  result  in  major  economic  losses.  These  losses
are  a  result  of  high  prevalence  in  combination  with  the
negative  effects  on  reproduction  and  the  general  health
condition  in  affected  herds.
Because  most  cattle  are  exposed  to  BVDV  during  their
lifetime,  vaccination  programs  are  used  extensively  to  pro-
tect  against  the  consequences  of  infection2.  However,  there
is  concern  that  conventional  vaccines  (attenuated  or  inactiv-
ated  formulations)  may  not  be  optimal  for  controlling  BVDV
infection15.  For  that  reason,  the  possibility  of  using  immu-
nodominant  proteins  of  BVDV  in  the  form  of  subunit  vaccines
has  gained  widespread  interest.
In  Argentina,  current  viral  vaccines  containing  BVDV  are
inactivated  formulations  combined  with  other  viral  and
bacterial  pathogens  used  for  the  prevention  of  infectious
diseases  belonging  to  the  reproductive  and  respiratory
complex.  In  this  respect,  these  vaccines  present  another
limitation  at  the  industry  scale  related  to  obtaining  enough
BVDV  viral  antigen.  Moreover,  while  it  is  believed  that
inactivated  vaccines  are  safe,  the  emergence  of  a  new
fatal  disease  named  neonatal  pancytopenia,  associated
with  the  use  of  inactivated  vaccines  against  BVDV,  has
been  reported  in  several  European  countries.  Marbin  Darbin
Bovine  Kidney  (MDBK)  cells  are  commonly  used  to  produce
BVDV  stocks,  which  are  sometimes  concentrated  during
the  manufacturing  process  of  vaccines.  Pancytopenia  is
triggered  when  vaccinated  animals  develop  autoantibodies
due  to  the  large  amount  of  MDBK  cellular  debris  present
in  the  formulations1.  To  face  all  these  difﬁculties,  it  is
undisputable  that  there  is  a  need  for  developing  new
generation  of  efﬁcient  and  safe  vaccines.
Subunit  vaccines  are  safe  and  could  allow  discrimination
between  infected  and  vaccinated  animals  (DIVA).  The  disad-
vantage  of  using  such  vaccines  is  the  difﬁculty  in  engineering
them  to  generate  an  adequate  protective  immune  response
at  a  cost  that  is  practical  for  veterinary  applications.  In  that
regard,  considerable  effort  is  under  way  to  devise  methods
of  enhancing  the  immunogenicity  of  such  vaccines.  One  of
the  most  successfully  employed  strategies  to  date  is  based
on  targeting  the  encoded  antigens  to  the  sites  of  immune
ﬂ
a
bnduction,  by  using  single-chain  variable  fragments  (scFv)  of
ntibodies  that  speciﬁcally  recognize  an  invariant  epitope
f  the  major  histocompatibility  complex  class  II  DR  molecule
n  the  surface  of  antigen-presenting  cells.  This  strategy  has
emonstrated  to  be  very  efﬁcient  in  improving  the  immune
esponses  induced  against  many  different  antigens,  either
sing  recombinant  subunit  proteins  or  DNA  vaccination5,13.
E2  is  the  major  glycoprotein  of  BVDV  envelope  and  the
ost  immunogenic  protein  of  this  virus.  Neutralizing  anti-
odies  induced  in  infected  animals  are  mainly  directed
gainst  E26. Thus,  the  use  of  immunodominant  BVDV  protein
E2)  as  a  subunit  vaccine  may  be  a  useful  tool  for  the  devel-
pment  of  efﬁcient  strategies  to  control  the  virus10,14.  The
aculovirus-insect  cell  expression  system  (Bevs,  the  abbre-
iature  of  Baculovirus  expression  vector  system)  is  one  of
he  most  widely  used  tools  for  the  high  level  expression  of
eterologous  proteins  in  a  eukaryotic  host  and  was  chosen  to
xpress  tE2  and  APCH-tE2  immunogens  in  this  work.  Advan-
ages  include  the  production  of  high  level  foreign  proteins
s  well  as  the  insect  cells  capable  of  post-translational  mod-
ﬁcations  similar  to  those  of  mammalian  cells.  In  addition,
he  Bevs  system  is  safe,  easy  to  use  and  readily  amenable
o  scale-up4. Up  to  now,  several  vaccines  produced  in
nsect  cells  are  commercially  available  for  veterinary  and
uman  use,  which  were  developed  against  cervical  can-
er,  prostate  cancer,  classical  swine  fever  virus  and  porcine
ircovirus3.
To  assess  the  enhancing  effect  of  APCH  on  E2  glycopro-
ein  immunogenicity,  expression  cassettes  encoding  either
 truncated  form  of  E2  (tE2)  or  tE2  fused  to  the  scfvAPCH
APCH-tE2)  were  constructed  using  the  pFast  Bac  Dual  vec-
or  (Invitrogen,  USA).  The  signal  peptide  melittin  was  added
o  both  constructions  in  order  to  secrete  the  recombi-
ant  proteins  into  the  insect  cell  culture  supernatants.  The
onstructs  were  sequenced  to  conﬁrm  their  integrity  prior
o  generating  recombinant  baculoviruses  (Macrogen,  Inc.,
orea),  which  were  generated  by  the  Bac-to-Bac  System
Invitrogen,  USA).
APCH-tE2  and  tE2  were  successfully  expressed  and
ecreted  into  the  supernatants  of  Spodoptera  frugiperda
SF9)  and  High  FiveTM (H5)  insect  cells  (Invitrogen,  USA).
oth  cell  lines  were  cultured  in  monolayers  and  spinner
asks  and  showed  similar  expression  levels,  reaching  5  mg/l
nd  12  mg/l  for  APCH-tE2  and  tE2  respectively,  as  assessed
y  ELISA9. Moreover,  it  could  be  veriﬁed  by  Western  blot  that
6  A.  Pecora  et  al.
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Figure  1  Detection  of  recombinant  proteins  tE2  and  APCH-tE2  by  Western  blot  analysis  under  non-reducing  conditions  in  10%
polyacrylamide  gels.  (a)  Monoclonal  antibody  (mAb)  anti  E2  2.9H.  Lane  1:  prestained  molecular  weight  (PageRulerTM,  Fermentas),
lane 2:  dimer  of  APCHt-E2  (150  kDa),  lane  3:  negative  SF9  supernatant.  (b)  mAb  anti  E2  CA1.  Lanes  1  and  2:  dimers  of  APCH-tE2
and tE2  (150  and  100  kDa),  lane  3:  negative  SF9  supernatant,  lane  4:  molecular  weight  marker.  (c)  mAb  anti-histidine  (Penta  His,
Qiagen). Lanes  1  and  2:  dimers  of  APCH-tE2  and  tE2,  lane  3:  negative  SF9  supernatant,  lane  4:  molecular  weight  marker.  The  arrows
s es  e
t
m
c
c
5
t
v
g
c
o
N
T
m
w
o
o
t
n
a
t
v
0
d
e
c
d
a
e
t
l
r
t
w
A
N
d
o
(
(
f
3
a
S
i
m
1
r
f
d
t
d
c
a
N
a
a
N
t
i
v
w
t
R
i
b
phow the  molecular  weight  of  each  stained  band  with  their  valu
he  recombinant  proteins  were  speciﬁcally  recognized  by  a
onoclonal  antibody  against  E2  protein  (Fig.  1).
The  guinea  pig  model  is  currently  used  to  test  killed
ommercial  formulations  of  reproductive  and  respiratory
omplex  vaccines  in  Argentina  (SENASA  Resolution  No.
89/12  related  to  animal  health);  since  the  levels  of  neu-
ralizing  antibodies  induced  in  guinea  pigs  were  statistically
alidated  as  a  reliable  indicator  to  predict  vaccine  immuno-
enicity  in  bovines7.  For  that  reason,  this  animal  model  was
hosen  to  test  the  vaccines  developed  in  this  work.
Brieﬂy,  35  male  guinea  pigs  strain  SSI:AL,  12  weeks
ld,  were  obtained  from  the  animal  care  facilities  of  the
ational  Institute  of  Agricultural  Technology  (INTA).
he  animals  were  randomly  divided  into  six  groups  (5  ani-
als  per  group)  prior  to  experimentation  and  immunized
ith  SF9  supernatants  containing:  (i)  1  g  of  tE2,  (ii)  0.5  g
f  tE2,  (iii)  0.2  g  of  tE2,  (iv)  1  g  of  APCH-tE2,  (v)  0.5  g
f  APCH-tE2  and  (vi)  0.2  g  of  APCH-tE2.  A  negative  con-
rol  group  (n  =  5)  was  inoculated  with  supernatants  from
on-infected  SF9  cells.  Vaccines  were  formulated  with  oily
djuvant  (w/o  Montanide  ISA  50,  Seppic,  France)  containing
he  antigens  in  a  proportion  adjuvant:antigen  of  60:40.  The
accines  were  applied  intramuscularly  (i.m.) in  a  volume  of
.6  ml  on  days  0  and  21.  Blood  samples  were  collected  on
ays  0,  30  and  60  post  immunization  (dpi)  and  sera  were
valuated  by  virus  neutralization  (VN),  following  the  proto-
ol  described  elsewhere8.  Neutralizing  antibody  titers  were
etermined  against  the  Singer  strain  by  the  method  of  Reed
nd  Muench11.
The  vaccine  based  on  APCH-tE2  was  signiﬁcantly  more
fﬁcient  in  the  induction  of  Nabs  than  the  one  based  on
E2  protein  alone.  This  could  be  better  appreciated  in  the
ower  doses  evaluated  (0.2  g  and  0.5  g)  (Fig.  2).  For  this
eason,  the  vaccine  based  on  the  fusion  protein  was  chosen
o  perform  the  cattle  vaccination  experiment.
To  that  end,  18  8--12  month  old  Aberdeen  Angus  calves
eighing  160--200  kg  were  obtained  from  INTA’s  closed  herd.
ll  animals  were  checked  for  the  absence  of  BVDV-speciﬁc
v
d
r
hxpressed  in  kDa.
abs  by  VN  and  BVDV  RNA  by  RT-PCR.  Bovines  were  ran-
omly  divided  into  3  groups  and  immunized  i.m. with  3  ml
f  the  oily  vaccine  containing:  (i)  1.5  g  of  APCH-tE2,
ii)  inactivated  BVDV  Singer  strain  1  ×  106.5 TDIC/ml  or
iii)  a  BVDV  non-related  protein;  on  days  0 and  30.  Sera
rom  all  animals  were  sampled  on  15,  30,  45,  60,  240  and
60  dpi  and  evaluated  by  VN.  Furthermore,  a  commercially
vailable  competitive  NS3  antibody  ELISA  kit  (Ingenasa,
pain)  was  used  and  serum  samples  from  the  three  exper-
mental  groups  of  bovines  were  processed  following  the
anufacturer’s  instructions  at  0,  60,  240  and  360  dpi.
Results  of  VN  showed  that  bovines  vaccinated  with  either
.5  g  of  APCH-tE2  or  an  inactivated  BVDV  showed  geomet-
ic  mean  titers  (GMT)  >2,  which  were  maintained  at  least
or  one  year  (Fig.  3a).  Negative  control  animals  did  not
evelop  Nabs  against  BVDV  in  all  the  time  points  analyzed;
herefore,  BVDV  circulation  throughout  the  experiment  was
iscarded.  Furthermore,  only  the  animals  from  the  positive
ontrol  group  showed  anti  NS3  antibodies,  highlighting  the
bility  of  the  vaccine  to  be  used  as  a  DIVA  tool  (Fig.  3b).
one  of  the  vaccinated  bovines  showed  local  reactions  or
dverse  effects  throughout  the  trial.
Mechanisms  underlying  protection  against  BVDV  infection
re  not  completely  understood;  however,  the  presence  of
abs  and  the  effective  priming  of  humoral  memory  appeared
o  be  important  factors  in  preventing  and  controlling  BVDV
nfection12.  In  this  work,  APCH-tE2  emulsiﬁed  in  an  oily  adju-
ant  induced  a  strong  humoral  response  in  cattle  (Fig.  3),
hich  was  comparable  to  those  required  for  a  satisfac-
ory  BVDV  killed  vaccine  according  to  CFR  (Code  of  Federal
egulations)  113.215.  The  low  dose  of  immunogen  admin-
stered  and  the  long-lasting  humoral  immunity  elicited  by
ovines  vaccinated  with  APCH-tE2  (at  least  up  to  one  year
ost  immunization)  demonstrate  that  subunit  recombinant
accines  can  be  optimized  in  order  to  avoid  high  protein
oses  or  repeated  boosters  to  induce  an  acceptable  immune
esponse.  Such  vaccines,  which  are  widely  applied  in  public
ealth  as  well  as  in  pets,  pig  farming  and  aviculture,  have
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Figure  2  Dose--response  of  tE2  and  APCH  tE2  in  guinea  pigs.  Experimental  groups  of  guinea  pigs  (n  =  5)  were  immunized  with
oily vaccines  containing  0.2,  0.5  or  1  g  of  tE2  (a)  or  APCH-tE2  (b).  A  negative  control  group  was  immunized  with  a  negative  SF9
supernatant. Animals  were  bled  on  30  and  60  days  post  immunization  (dpi)  and  sera  were  evaluated  by  VN.  Arrows  indicate  times  of
vaccination. The  results  of  the  VN  were  statistically  evaluated  by  an
between groups.  Statistical  signiﬁcance  was  assessed  at  p  <0.05  for  
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Figure  3  Vaccination  experiment  in  cattle.  (a)  Calves  were
immunized  twice  with  1.5  g  of  APCH-tE2.  On  15,  30,  45,  60,
240 and  360  days  post  immunization  (dpi)  animals  were  bled  and
sera were  evaluated  by  VN.  A  positive  control  group  was  immu-
nized  with  an  inactivated  vaccine  containing  106.5 TDIC50/ml
BVDV, Singer  strain  and  a  negative  control  group  was  vacci-
nated with  a  formulation  of  a  negative  SF9  supernatant.  Arrows
indicate  times  of  vaccination.  Differences  in  the  geometric
mean  titer  (GMT)  for  neutralizing  antibodies  among  groups
were evaluated  by  ANOVA  under  a  model  of  repeated  meas-
ures throughout  time,  followed  by  a  general  contrast  post
ANOVA  test.  Statistical  signiﬁcance  was  assessed  at  p  <0.05
for all  comparisons.  (b)  Antibody  response  against  BVDV  NS3
(p80) was  determined  using  the  commercial  NS3-ELISA  Ingen-
zim BVD  Compac  kit,  (Ingenasa,  Spain);  +:  positive,  −:  negative.
Cattle  management,  inoculation,  and  sample  collection  were
conducted  by  trained  personnel  under  the  supervision  of  a
veterinarian  and  in  accordance  with  protocols  approved  by
INTA’s Ethical  Committee  of  Animal  Welfare  (CICUAE,  Protocol
23/2012).
n
b
N
a
D
s
o
i
t
r
t
u
f
B
o
f
E
P
d
w
c
M
b
C
d
R
d
C
Talysis  of  variance  (ANOVA),  determining  signiﬁcant  differences
all  comparisons,  using  the  Statistix  8.0  Analytical  Software.
ot  yet  been  extended  to  cattle,  not  having  to  date  recom-
inant  vaccines  on  the  market.  Furthermore,  lack  of  anti
S3  antibodies  in  animals  vaccinated  with  APCH-tE2  reli-
bly  indicates  that  the  vaccine  can  be  accurately  used  as  a
IVA  tool,  since  both  natural  BVDV  infection  and  the  use  of
ome  killed  or  attenuated  vaccines  elicit  the  production
f  antibodies  against  that  protein,  among  others2.
Given  these  encouraging  results,  this  novel  vaccine
s  currently  undergoing  scale-up  and  was  transferred  to
he  private  sector.  Nowadays,  it  is  being  evaluated  for
egistration  as  the  ﬁrst  Argentinean  subunit  vaccine  for  cat-
le.
Moreover,  we  are  currently  working  to  enhance  this  sub-
nit  vaccine  by  adding  the  recombinant  E2  glycoprotein
rom  other  BVDV  genotypes  in  order  to  achieve  broader
VDV  antigenic  coverage.  Future  studies  will  be  focused
n  performing  a  vaccination-challenge  assay  with  this  novel
ormulation.
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